AKT1 and breast carcinoma: When breast cancer cells with either wild-type (BT474) or activating mutations in both PI3K/Akt/mTORC1 and MAPK pathways (SUM159PT) were analyzed, we observed that the regulation of eIF4B, S6 and PDCD4 mostly relies on the agonist-stimulated pathway.